Evidence map›Paper›PMID 17073823›Full record

ArticleThe Biochemical journal2007

Kinetic properties of mutant deoxyguanosine kinase in a case of reversible hepatic mtDNA depletion.

Bénédicte Mousson de Camaret, Jan-Willem Taanman, Sylvie Padet, Maïté Chassagne, Martine Mayençon, Pascale Clerc-Renaud, Ginette Mandon, Marie-Thérèse Zabot, Alain Lachaux, Dominique Bozon

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in The Biochemical journal, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Case report: NovelFrontiers in pediatrics · 2023
    Article
  5. Article
  6. [DGUOK-related mitochondrial DNA depletion syndrome: a case report and literature review].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2020
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2013
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Defects in mitochondrial DNA replication and human disease.Critical reviews in biochemistry and molecular biology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Bénédicte Mousson de CamaretLaboratoire de Biochimie Pédiatrique, Hôpital Debrousse, Hospices Civils de Lyon, 69322 Lyon, France. mousson@univ-lyon1.fr
Jan-Willem Taanman
Sylvie Padet
Maïté Chassagne
Martine Mayençon
Pascale Clerc-Renaud
Ginette Mandon
Marie-Thérèse Zabot
Alain Lachaux
Dominique Bozon
Hôpital Debrousse · FRHôpital Edouard Herriot · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DGUOK [dG (deoxyguanosine) kinase] is one of the two mitochondrial deoxynucleoside salvage pathway enzymes involved in precursor synthesis for mtDNA (mitochondrial DNA) replication. DGUOK is responsible for the initial rate-limiting phosphorylation of the purine deoxynucleosides, using a nucleoside triphosphate as phosphate donor. Mutations in the DGUOK gene are associated with the hepato-specific and hepatocerebral forms of MDS (mtDNA depletion syndrome). We identified two missense mutations (N46S and L266R) in the DGUOK gene of a previously reported child, now 10 years old, who presented with an unusual revertant phenotype of liver MDS. The kinetic properties of normal and mutant DGUOK were studied in mitochondrial preparations from cultured skin fibroblasts, using an optimized methodology. The N46S/L266R DGUOK showed 14 and 10% residual activity as compared with controls with dG and deoxyadenosine as phosphate acceptors respectively. Similar apparent negative co-operativity in the binding of the phosphate acceptors to the wild-type enzyme was found for the mutant. In contrast, abnormal bimodal kinetics were shown with ATP as the phosphate donor, suggesting an impairment of the ATP binding mode at the phosphate donor site. No kinetic behaviours were found for two other patients with splicing defects or premature stop codon. The present study represents the first characterization of the enzymatic kinetic properties of normal and mutant DGUOK in organello and our optimized protocol allowed us to demonstrate a residual activity in skin fibroblast mitochondria from a patient with a revertant phenotype of MDS. The residual DGUOK activity may play a crucial role in the phenotype reversal.

Indexed as

Cells, CulturedChild, PreschoolDNA, MitochondrialFibroblastsGene DeletionHumansInfantInfant, NewbornKineticsLiverMitochondriaMutationPhosphatesPhosphotransferases (Alcohol Group Acceptor)RNA, Messengerdeoxyguanosine kinaseDNA, MitochondrialPhosphatesPhosphotransferases (Alcohol Group Acceptor)RNA, Messenger

Identifiers

PMID17073823
PMCPMC1798436
OpenAlexW2006892643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.